Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development. The company was founded by Thomas J. Schuetz on March 20, 2018 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced today that it will present preclinical data on CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans

BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported fourth quarter and full year 2021 financial results and provided a corporate update.

Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its IND application for CTX-009, enabling the company to initiate a global Phase 2 clinical trial for CTX-009 in patients who have advanced Biliary Tract Cancers (BTC) in the United States and South Korea. Compass plans to include the existing Phase 2 in South Korea in this global study, allowing it to expand the ongoing study of CTX-009 under this IND. CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A).

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics, Inc. (Nasdaq: CMPX) will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wed., Jan. 12, 2022.

Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

Liquidia Technologies Inc

 Orbital Energy Group, Inc.

OpGen

PetVivo Holdings

Hot penny stocks insiders are buying in November The post 5 Penny Stocks To Buy Now According To Insiders In November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Buy Now According To Insiders In November 2021

BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

BOSTON--(BUSINESS WIRE)---- $CMPX #ABL001--Compass Therapeutics reports on the clinical development of CTX-009 (ABL001), a dual anti-angiogenic bispecific antibody targeting DLL4 and VEGF-A.

Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle

BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)-- #AACR--CTX-009 (ABL001/ES104) clinical data presented today at the New Drugs on the Horizon plenary session of 2021 AACR-NCI-EORTC International Conference

CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BOSTON--(BUSINESS WIRE)-- #AACR--CTX-009 clinical data was selected to be a Plenary Presentation at the AACR-NCI-EORTC international conference.

Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

News for Compass Therapeutics Stock (CMPX)